Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 8/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7130597 | 1.00 | AKR1C3 (0.47) | AKR1C3APEX1CES2CES1ALDH1A1 | |
| Guanidine SCHEMBL7163632 | 0.90 | AKR1C3 (0.40) | AKR1C3APEX1CES2CES1 | |
| Guanidine SCHEMBL7163626 | 0.90 | AKR1C3 (0.40) | AKR1C3APEX1CES2CES1 | |
| SCHEMBL7138000 | 0.82 | AKR1C3 (0.44) | AKR1C3APEX1CES2CES1 | |
| SCHEMBL7137993 | 0.82 | AKR1C3 (0.44) | AKR1C3APEX1CES2CES1 | |
| SCHEMBL7008624 | 0.82 | AKR1C3 (0.53) | AKR1C3APEX1CES2CES1CYP1A2 | |
| SCHEMBL7008627 | 0.82 | AKR1C3 (0.53) | AKR1C3APEX1CES2CES1CYP1A2 | |
| SCHEMBL7004949 | 0.81 | AKR1C3 (0.44) | AKR1C3APEX1ALDH1A1CYP2C9 | |
| SCHEMBL7004945 | 0.81 | AKR1C3 (0.44) | AKR1C3APEX1ALDH1A1CYP2C9 | |
| SCHEMBL12276072 | 0.80 | POLB (0.34) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6504057-B2 | Anti-arrhythmia, -ischemic, -proliferative and -diabetic agents; cardiotonic, necrosis; angina pectoris; peripheral and central nervous systems; protecting/preserving organs; inhibition of Na+/H+ exchange; diagnosis hypertonia | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-01-07 | — | — | US | disclosed |
| US-20020123529-A1 | Anti-arrhythmia, -ischemic, -proliferative and -diabetic agents; cardiotonic, necrosis; angina pectoris; peripheral and central nervous systems; protecting/preserving organs; inhibition of Na+/H+ exchange; diagnosis hypertonia | HOECHST AKTIENGESELLSCHAFT | 2002-09-05 | — | — | US | disclosed |
| US-20010020042-A1 | Cardiovascular disorders | HOECHST AKTIENGESELLSCHAFT | 2001-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123529-A1 | Anti-arrhythmia, -ischemic, -proliferative and -diabetic agents; cardiotonic, necrosis; angina pectoris; peripheral and central nervous systems; protecting/preserving organs; inhibition of Na+/H+ exchange; diagnosis hypertonia | TNNI3, SLC5A1, TNNC1 | AKR1C3 613/4885APEX1 2554/4885CES2 2041/4885 |
| US-20010020042-A1 | Cardiovascular disorders | SLC5A1, SLC9A1, SLC28A1 | AKR1C3 393/4885APEX1 971/4885CES2 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.